🇺🇸 FDA
Patent

US 12145922

Selective D3 dopamine receptor agonists and methods of their use

granted A61PA61P25/14A61P25/16

Quick answer

US patent 12145922 (Selective D3 dopamine receptor agonists and methods of their use) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61P, A61P25/14, A61P25/16, A61P25/28